M. Hatton
About
M. Hatton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiation.
According to data from OpenAlex, M. Hatton has authored 96 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 30 papers in Radiation. Recurrent topics in M. Hatton's work include Lung Cancer Diagnosis and Treatment (39 papers), Lung Cancer Research Studies (25 papers) and Advanced Radiotherapy Techniques (23 papers). M. Hatton is often cited by papers focused on Lung Cancer Diagnosis and Treatment (39 papers), Lung Cancer Research Studies (25 papers) and Advanced Radiotherapy Techniques (23 papers). M. Hatton collaborates with scholars based in United Kingdom, Netherlands and United States. M. Hatton's co-authors include Corinne Faivre‐Finn, Suresh Senan, Ben J. Slotman, Elaine M. Rankin, M. Snee, Laurence Collette, G. Kramer, Pieter E. Postmus, E. Musat and Rob H. Ireland and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
M. Hatton
89 papers receiving 3.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| M. Hatton United Kingdom | 25 | 2.2k | 2.0k | 1.0k | 562 | 473 | 96 | 3.3k | ||
| Jeffrey A. Bogart United States | 33 | 2.7k 1.2× | 1.8k 0.9× | 653 0.6× | 781 1.4× | 871 1.8× | 127 | 3.8k | ||
| A. Sun Canada | 37 | 2.5k 1.1× | 1.7k 0.9× | 593 0.6× | 1.1k 1.9× | 891 1.9× | 162 | 4.9k | ||
| Hirohito Tada Japan | 27 | 3.3k 1.5× | 1.9k 1.0× | 629 0.6× | 712 1.3× | 60 0.1× | 84 | 4.3k | ||
| Mark Konijnenberg Netherlands | 41 | 1.5k 0.7× | 1.8k 0.9× | 1.8k 1.8× | 3.8k 6.8× | 1.1k 2.3× | 139 | 5.4k | ||
| Ralph A. Bundschuh Germany | 33 | 1.3k 0.6× | 701 0.4× | 361 0.3× | 2.7k 4.8× | 359 0.8× | 138 | 3.5k | ||
| Peter Bernhardt Sweden | 37 | 931 0.4× | 1.2k 0.6× | 1.3k 1.3× | 2.3k 4.0× | 500 1.1× | 130 | 3.8k | ||
| Samer Ezziddin Germany | 37 | 1.4k 0.7× | 1.8k 0.9× | 1.6k 1.5× | 1.9k 3.4× | 194 0.4× | 182 | 4.0k | ||
| Ramesh Rengan United States | 33 | 2.2k 1.0× | 914 0.5× | 289 0.3× | 1.3k 2.2× | 1.2k 2.5× | 157 | 3.5k | ||
| Masahiko Koizumi Japan | 25 | 1.2k 0.5× | 484 0.2× | 208 0.2× | 670 1.2× | 904 1.9× | 186 | 2.5k | ||
| Elizabeth Gore United States | 33 | 3.8k 1.7× | 2.0k 1.0× | 554 0.5× | 1.2k 2.2× | 1.2k 2.5× | 133 | 5.2k |
Countries citing papers authored by M. Hatton
Since
Specialization
Citations
This map shows the geographic impact of M. Hatton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Hatton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Hatton more than expected).
Fields of papers citing papers by M. Hatton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by M. Hatton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Hatton. The network helps show where M. Hatton may publish in the future.
Co-authorship network of co-authors of M. Hatton
This figure shows the co-authorship network connecting the top 25 collaborators of M. Hatton. A scholar is included among the top collaborators of M. Hatton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Hatton. M. Hatton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yan, Tingting, et al.. (2024). When Complexity Meets Complexity: COVID ‐19‐Induced Supply Chain Disruptions and Strategy Portfolio Efficiency. Journal of Operations Management. 71(1). 109–129.
2.
Woolf, David, Nichola Downs, Chris Sutton, et al.. (2024). 209 ThOracic Umbrella RadIotherapy STudy in stage IV NSCLC: TOURIST. Lung Cancer. 190. 107770–107770.
3.
Brown, Sarah, Vicky M. Coyle, K. Franks, et al.. (2023). P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. Journal of Thoracic Oncology. 18(11). S296–S297.
4.
Khan, Sam, Robert C. Rintoul, Coral Pepper, et al.. (2023). Lung cancer in never smokers (LCINS): development of a UK national research strategy. PubMed. 1(1). 21–21.
5.
Faivre‐Finn, Corinne, John D. Fenwick, K. Franks, et al.. (2020). Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic. Clinical Oncology. 32(8). 481–489.
6.
Bayman, N., K. Franks, Susan Harden, et al.. (2020). Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. International Journal of Radiation Oncology*Biology*Physics. 109(5). 1341–1348.
7.
Robinson, Stephen, et al.. (2019). Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules. Radiotherapy and Oncology. 143. 37–43.
8.
Lester, J., C. Esler, Elizabeth Toy, et al.. (2018). Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. Clinical Oncology. 30(3). 144–150.
9.
Tahir, Bilal, Paul Hughes, Stephen Robinson, et al.. (2018). Spatial Comparison of CT-Based Surrogates of Lung Ventilation With Hyperpolarized Helium-3 and Xenon-129 Gas MRI in Patients Undergoing Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 102(4). 1276–1286.
10.
Slotman, Ben J., Corinne Faivre‐Finn, Harm van Tinteren, et al.. (2017). Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer. 108. 150–153.
11.
Ireland, Rob H., et al.. (2016). Functional Image-guided Radiotherapy Planning for Normal Lung Avoidance. Clinical Oncology. 28(11). 695–707.
12.
Din, Omar, Susan Harden, Emma Hudson, et al.. (2013). Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: Results from 4 UK centres. Radiotherapy and Oncology. 109(1). 8–12.
13.
Hatton, M., et al.. (2010). Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network — Are We Treating the Right Patients?. Clinical Oncology. 22(4). 289–293.
14.
Hatton, M., Matthew Nankivell, Stephen Falk, et al.. (2010). Induction Chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer: The MRC INCH Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 81(3). 712–718.
15.
Hatton, M. & Jocelyne Martin. (2010). Continuous Hyperfractionated Accelerated Radiotherapy (CHART) and Non-conventionally Fractionated Radiotherapy in the Treatment of Non-small Cell Lung Cancer: a Review and Consideration of Future Directions. Clinical Oncology. 22(5). 356–364.
16.
Slotman, Ben J., Murielle Mauer, Andrew Bottomley, et al.. (2008). Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. Journal of Clinical Oncology. 27(1). 78–84.
17.
Din, Omar, J.F. Lester, Alison Cameron, et al.. (2008). Routine Use of Continuous, Hyperfractionated, Accelerated Radiotherapy for Non–Small-Cell Lung Cancer: A Five-Center Experience. International Journal of Radiation Oncology*Biology*Physics. 72(3). 716–722.
18.
Lee, Siow Ming, Penella J. Woll, M. Hatton, et al.. (2007). A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC). UCL Discovery (University College London).
19.
Lee, Siow Ming, Penella J. Woll, Lindsay E. James, et al.. (2007). PRS-04: A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC). Journal of Thoracic Oncology. 2(8). S306–S307.
20.
Brown, James E., et al.. (2003). Chemotherapy, Erythropoietin and Bloodless Surgery in a Jehovah's Witness. Clinical Oncology. 15(7). 371–377.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jeffrey A. Bogart Breakdown of academic impact, for papers by A. Sun Breakdown of academic impact, for papers by Hirohito Tada Breakdown of academic impact, for papers by Mark Konijnenberg Breakdown of academic impact, for papers by Ralph A. Bundschuh Breakdown of academic impact, for papers by Peter Bernhardt Breakdown of academic impact, for papers by Samer Ezziddin Breakdown of academic impact, for papers by Ramesh Rengan Breakdown of academic impact, for papers by Masahiko Koizumi Breakdown of academic impact, for papers by Elizabeth Gore